Nonprofit hospitals under the taxman’s magnifying glass

Nonprofit hospitals getting challenged on their tax-exempt status have been much in the news of late.  

  • On Jan. 8, the Chicago Tribune reported on a decision by an Illinois appeals court to reopen argument over the constitutionality of a 2012 law allowing hospitals to claim exemption from various taxes.
  • The same day, NJ.com ran a story on the Garden State’s nonprofit hospitals facing the prospect of paying fees to cover public-safety services and help reduce property taxes.
  • Also on Jan. 8, the Health Affairs blog stressed that, going forward, “an important question becomes whether national health policies applicable to tax-exempt hospitals should be further revised to more actively encourage investments that improve health on a community-wide basis.”

The flurry may partly trace to a January 2012 Health Affairs study showing that some tax-exempt hospitals aren’t spending any more than their for-profit counterparts on charity care or community health.

Last summer, in advance of the study’s publication, co-author Renee Hsia, MD, MSc, told the Washington Post that the takeaway from the research “is not that we should not be giving tax breaks, but that there should be a little more accountability.”

Hsia added, “These are exemptions that, if we didn’t have them, could fund education, water or public utilities.”

For those inclined to explore the questions at hand in greater detail, the Internal Revenue Service offers for online consideration the final report on its Nonprofit Hospitals Project.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.